Nachrichten zur Sarepta Therapeutics Aktie

Why Is Sarepta Therapeutics (SRPT) Up 24.2% Since Last Earnings Report?

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates…

SRPT Stock Surges on Promising Early Results From siRNA Programs

Sarepta Therapeutics shares surge 35% as early data from two siRNA therapies show strong target knockdown, safety and muscle delivery…

Sarepta Therapeutics (SRPT) Soars 35.0%: Is Further Upside Left in the Stock?

Sarepta Therapeutics (SRPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings…

Sarepta Therapeutics, Inc. (SRPT) Discusses Preliminary Phase I/II Data for SRP-1001 in FSHD1 and SRP-1003 in DM1 Transcript

…

Market movers: Sarepta Therapeutics, Chewy, Merck, Cognyte Software…

…

Sarepta Therapeutics’ experimental siRNA therapies show promising early results

Sarepta Therapeutics Inc (NASDAQ:SRPT) shares surged almost 26% to about $22 after the biotechnology company shared early clinical results from…

Compared to Estimates, Sarepta Therapeutics (SRPT) Q4 Earnings: A Look at Key Metrics

Although the revenue and EPS for Sarepta Therapeutics (SRPT) give a sense of how its business performed in the quarter…

Sarepta (SRPT) Q4 2025 Earnings Call Transcript

Image source: The Motley Fool.DATEFeb. 25, 2026 at 4:30 p.m. ETCALL PARTICIPANTSChief Executive Officer — Douglas IngramChief Commercial Officer —…

Sarepta Therapeutics stock rises on Japan launch of ELEVIDYS

Sarepta Therapeutics stock rises on Japan launch of ELEVIDYS…

Sarepta Therapeutics, Inc. (SRPT) Discusses 3-Year Topline Results From EMBARK Phase 3 Trial of ELEVIDYS in Duchenne Muscular Dystrophy - Slideshow

…

Sarepta Therapeutics, Inc. (SRPT) Discusses 3-Year Topline Results From EMBARK Phase 3 Trial of ELEVIDYS in Duchenne Muscular Dystrophy Transcript

…

Sarepta Therapeutics (SRPT) Upgraded to Buy: What Does It Mean for the Stock?

Sarepta Therapeutics (SRPT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to…

Market movers: Sarepta Therapeutics, US Rare Earth, SkyWater Technology, CoreWeave...

…

Sarepta Therapeutics shares rise on positive Duchenne gene therapy data

Sarepta Therapeutics Inc (NASDAQ:SRPT) shares moved higher in early trade on Monday as it reported positive topline three-year results from…

Sarepta Therapeutics, Inc. (SRPT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

…

Sarepta Therapeutics: Why The Newborn Screening Decision For DMD Matters More Than The Stock Move Suggests

…

Sarepta Therapeutics Aktie: Zurück auf dem Radar! Kommt jetzt der nächste Kursschub?

Los Angeles (www.aktiencheck.de) - Sarepta Therapeutics-Aktienanalyse von Wedbush Securities:Wedbush habe die Coverage für die Aktie von Sarepta Therapeutics Inc. (ISIN:…

Why Is Sarepta Therapeutics (SRPT) Up 26.4% Since Last Earnings Report?

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. Whats next for the stock? We take a look at earnings estimates…

Sarepta Therapeutics (SRPT) Reports Q3 Loss, Beats Revenue Estimates

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of -1,400.00% and +13.26%, respectively, for the quarter ended September 2025. Do…

After-hours movers: Palantir, Hims & Hers Health, Sarepta Therapeutics, Sanmina By Investing.com

After-hours movers: Palantir, Hims & Hers Health, Sarepta Therapeutics, Sanmina…

Sarepta Therapeutics Aktienanalyse: Outperformer trotz Unsicherheiten bei Elevidys!

Bad Marienberg (www.aktiencheck.de)???? Sarepta Aktie vor dem Turnaround? Risiko-Chance-Verhältnis laut BMO jetzt attraktivAm 22. September 2025 hat BMO Capital seine…

Sarepta Therapeutics: BMO Capital sieht 168 % Kurspotenzial - Die Akzeptanz von Elevidys nimmt gemäß der Experten zu

Sarepta Therapeutics (SRPT) (i.) hat sich als führendes Unternehmen in der Präzisions-Gentherapie etabliert, insbesondere im Bereich der seltenen neuromuskulären Erkrankungen…

Sarepta Therapeutics (SRPT) Reports Q2 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Sarepta Therapeutics (SRPT) give a sense of how its business performed in the quarter…

SAREPTA LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. and Encourages Investors to Contact the Firm

NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights…

Stocks making the biggest moves midday: Harley-Davidson, Wingstop, Sarepta Therapeutics and more

These are the stocks posting the largest moves midday.…

Sarepta Therapeutics (SRPT) to Report Q2 Results: Wall Street Expects Earnings Growth

Sarepta Therapeutics (SRPT) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its…

Sarepta Therapeutics Aktie: Elevidys-Rückkehr stärkt Kursfantasie

New York (www.aktiencheck.de) - Sarepta Therapeutics-Aktienanalyse von TD Cowen: Die Analysten von TD Cowen raten die Aktie von Sarepta Therapeutics Inc.…

Sarepta Therapeutics Aktie nach FDA-Wende hochgestuft - Worst Case vorerst vom Tisch

London (www.aktiencheck.de) - Sarepta Therapeutics-Aktienanalyse von Barclays: Gena Wang von Barclays stuft die Aktie von Sarepta Therapeutics Inc. (ISIN: US8036071004, WKN:…

Barclays upgrades Sarepta Therapeutics stock rating on FDA hold removal By Investing.com

Barclays upgrades Sarepta Therapeutics stock rating on FDA hold removal…

Market movers: PayPal, Sarepta Therapeutics, UnitedHealth...

…

Sarepta Therapeutics Aktie: Vorsichtig optimistischer Lichtblick für Anleger!

New York (www.aktiencheck.de) - Sarepta Therapeutics-Aktienanalyse von Morgan Stanley: Morgan Stanley habe das Kursziel für die Aktie von Sarepta Therapeutics Inc.…

Sarepta Therapeutics Aktie: Positives Signal, aber Vorsicht weiter angebracht!

Toronto (www.aktiencheck.de) - Sarepta Therapeutics-Aktienanalyse von BMO Capital Markets: Die Analysten von BMO Capital Markets hätten in einer aktuellen Studie das…

Sarepta Therapeutics Aktie vor Comeback? FDA-Hoffnung lässt Kursziel auf 15 USD steigen!

Minneapolis (www.aktiencheck.de) - Sarepta Therapeutics-Aktienanalyse von Piper Sandler: Der Analyst Biren Amin von Piper Sandler habe in einer aktuellen Analyse das…

Stocks making the biggest moves premarket: Novo Nordisk, Whirlpool, Sarepta Therapeutics and more

These are the stocks posting the largest moves in premarket trading.…

Sarepta Therapeutics Aktie: Kaum Potenzial? Bernstein glaubt nicht an Elevidys-Zulassung

New York (www.aktiencheck.de) - Sarepta Therapeutics-Aktienanalyse von Sanford C. Bernstein & Co: Die Analysten von Sanford C. Bernstein & Co stufen…

Sarepta Therapeutics Aktie: Wainwright rät weiter zum Verkauf - trotz Elevidys-Freigabe

New York (www.aktiencheck.de) - Sarepta Therapeutics-Aktienanalyse von H.C. Wainwright & Co: Die Analysten von H.C. Wainwright & Co raten die Aktie…

Sarepta shares rebound after shipments of gene therapy Elevidys resume in US

Sarepta Therapeutics shares surged more than 30% before the bell on Tuesday, as analysts said the resumption of U.S. shipments…

Sarepta shares surge after FDA lifts pause on muscular dystrophy treatment

Sarepta Therapeutics Inc (NASDAQ:SRPT) shares jumped 25% at the open on Tuesday after the US Food and Drug Administration recommended…

Sarepta Therapeutics stock rating upgraded by JPMorgan on FDA decision By Investing.com

Sarepta Therapeutics stock rating upgraded by JPMorgan on FDA decision…

Sarepta Therapeutics gets FDA green light to resume Elevidys for DMD By Investing.com

Sarepta Therapeutics gets FDA green light to resume Elevidys for DMD…

Sarepta Therapeutics Aktie: Analyst sieht 0 USD Kursziel - EMA lehnt Elevidys ab

New York (www.aktiencheck.de) - Sarepta Therapeutics-Aktienanalyse von H.C. Wainwright & Co.: Der H.C. Wainwright-Analyst Mitchell Kapoor hat sein "sell"-Rating für die…

Sarepta Therapeutics Aktie: Elevidys-Auslieferung gestoppt - Kursziel nahezu halbiert

London (www.aktiencheck.de) - Sarepta Therapeutics-Aktienanalyse von Barclays: Die Analysten von Barclays stufen die Aktie von Sarepta Therapeutics Inc. (ISIN: US8036071004, WKN:…

SRPT STOCK UPDATE: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is being Sued for Securities Fraud – Contact BFA Law by August 25 Class Action Deadline

Sarepta Therapeutics, Inc. investors that lost money are notified to contact BFA Law before the August 25, 2025 securities fraud…

dpa-AFX ProFeed